Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 1.18% 85.50 83.00 88.00 85.50 82.00 84.50 37,150 11:59:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -9.1 -8.0 - 100

Shield Therapeutics Share Discussion Threads

Showing 5876 to 5899 of 6225 messages
Chat Pages: Latest  237  236  235  234  233  232  231  230  229  228  227  226  Older
DateSubjectAuthorDiscuss
21/5/2020
15:00
He probably would not be allowed to say. Or are you suggesting he knew, and there has been no benefit, ie he lied ? I can email them that suggestion !
peachie 74
21/5/2020
14:58
CEO IV comment was in is interview on proactive reference market update and is comment was he didn’t know if Nordgine were benefiting from c19 and that is the issue why didn’t he know because they have little communication. I put this to various posters if you were the CEO would you know if Nordgine had benefited from the current IV issue in the last 3 months end of
best1467
21/5/2020
14:52
Btw. 110 mill market cap seems very low to me with the size of the billion dollar market this is feeding into
peachie 74
21/5/2020
14:50
Best , in all due respect , you have no idea behind his reasons. What’s the worse thing, he has found out Feraccru is unsafe or no efficacy ? No. Of course not. There are millions of professional or private reasons. How do you not know a family member has cancer for example ? Extreme. But you just don’t know. The product still is what it is. Nothing changed there. That’s the main thing At least the BB has livened up !
peachie 74
21/5/2020
14:39
Yes when it’s the founder of the company and the main driving force in the buisness
best1467
21/5/2020
14:26
Is changes in board members a big deal? People leave jobs all the time.
78steve
21/5/2020
13:48
ekcs - that was a good post, indeed. However, I would beg to differ with you on this part of it 'no point in moaning about an RNS that is basically full of detail that had been flagged already'. Both the quote from, and the subsequent resignation of the NEC were, to the best of my knowledge introduced today in the aforementioned RNS. Therefore, despite all we have stated, it is not tremendously reassuring for him to reiterate all we know followed by a dramatic negative sentence topped off with his impending departure!! You'd have to say, Mr Market appears to agree somewhat. Hope it's just (another) temporary hiccup on the road to success for all. Good luck as ever. No more Shergar analogies from me - it didn't end very well there.
daveboy1
21/5/2020
13:23
They did mention it in the trading update actually... or it may have been in a CEO interview. I’ll check later. But was mentioned and if I remember the context was that it was too early to say
peachie 74
21/5/2020
13:16
And yet Peachie absolutely no mention from the company that IV is impacted in hospitals and that they expect to see uptick in sales due to this. They feel the need to inform everyone that the company may not exist next year due to cash flow which apparently is just covering all bases yet there is not one snippet from them that they expect to take advantage of this IV delivery issue that people keep talking about in hospitals. If there was IV delivery issue that the product could address then we would have heard something by now, especially as hospital admissions due to Covid have peaked.
lako42
21/5/2020
13:10
You would think the US would be prioritising this now more than ever as presumably every patient who could be taking tablet where possible instead of intravenous should be to free up hospital spaces for covid patients. You'd think this a no brainer in certain cases. tablets or IV being hooked up in bed i know which one i would choose.
78steve
21/5/2020
12:50
EKCS... great post mate. All true and gives a great bit of clarity. There is no way the current shift in healthcare resources has not severely impacted IV delivery. I’d be amazed if Shield don’t benefit from it both short and long term. ASK are a massive organisation. 1000 reps. Pushing Feraccru into the massive Asian market. Ok Norgine May be seemingly sluggish to some. But how do we know what’s going on behind the scenes. They were 80% up 18 to 19. It’s only going to get better. Anyway. IMO this has a lot lot to offer the world DYOR
peachie 74
21/5/2020
12:35
Time for people to take a breath and consider the actual situation. None of the information in the RNS is a surprise as they are pretty good at flagging what's coming either through trading updates or interviews on Vox or Proactive etc... People come and go... the IP, the product and the market it addresses is what counts here… and those things can be clearly assessed from presentations they've shared with all of us previously. US DEAL: Getting a US deal done in the current climate must be quite tough for all the obvious logistical complexities coronavirus has created. Plus US players will probably be trying to conserve cash as their reps cannot be out on the road calling on docs, so revenues for non-life-saving/essential products will have reduced for the moment yet STX wants them to pay a multi-million $ upfront... at a time when cash is king. The US is already opening up again so hopefully that is all just transient. So, the company needs to be sure it has the cash such that it doesn't get squeezed in US licence negotiations, which presumably are now well-advanced from their announcements. As for the CEO... He had obviously been around since the start, had built the company from nothing and has a very substantial investment (money and time) in the company... no doubt more than all of us... plus he is still in a supportive role for the US project so I guess not getting a salary... Who knows what his personal reasons were for stepping down but they are not relevant as clearly and importantly he is aligned with us lot, as his upside is his 10% stake. What bigger incentive! Non-Exec Chairman - who knows... who cares... when the company is clearly looking to become a cash cow/royalty play through the US deal. Stay patient or get out seem to be the options... no point in moaning about an RNS that is basically full of detail that had been flagged already. Looking at the volumes it is just PIs trading, with institutional holders staying put. Tat says a a lot as that's who the company and its brokers will have been/will be talking to. DYOR.
ekcs
21/5/2020
12:15
Haha. Shergar ... made me laugh. Good analogy to be fair. I’m not going to say the CEO and chairman stepping back is amazing for the company. But that’s business. And the US deal is taking time. TBF they always said it might as to get the right deal. This will give them cash well into the future hopefully. But yes I’d like the US deal done too. But I have done a lot of research into iron deficiency and this product as well as others. And to use your analogy , Feraccru is the Shergar equivalent in the Fe deficiency world. The jockey can improve and change. But you need the best horse. Shield have IMO
peachie 74
21/5/2020
11:36
That Sherman comment sums it up perfectly and NBG not everyone as been happy for sometime the company as a great product but as been poorly managed and communicated for sometime now.
best1467
21/5/2020
11:19
The spread is also eye watering.Seems to vary between 3% and 5%Just to sell and buy back in will cost 6% at least
kop202
21/5/2020
11:13
Peachie - good points, all of them. I want it to work, trust me (even added today with other funds!) My concern is some other facts that you omitted. 1)CEO and Co-founder departs. 2)New CEO appointed is former CFO, who looks like a fish out of water pre-cooking pot! 3)Dwindling cash described thus 'the cash runway extends into the first quarter of 2021 and there is therefore a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern' by NEC who then departs. Market reaction seems understandable from this angle to me. It's always 'up in the air' with this company, and it shouldn't be with what they have IMHO. Rather akin to having Shergar with a 16 stone blob sitting on his back !!
daveboy1
21/5/2020
11:10
If you sell out at these levels you may well face a struggle getting back in. When the news flow starts , and this gets momentum it flies. We saw that a few weeks ago.
peachie 74
21/5/2020
11:02
I've topped up sub 100p today lets have US mega deal now please
78steve
21/5/2020
10:55
The free float is only 30%Volatility is always likely with fewer shares available to trade especially when all trades controlled through MM
kop202
21/5/2020
10:20
Back to 55p... Please Monty don’t sell them and become an obvious deramper. Sell and move on pal or give justifiably reasons. In every bit of news flow the company have emphasised that there is fantastic interest in the US and the have multiple options. So are they blatantly lying to the markets ? I don’t think so. Is there another product on the market like this that can compete with IV ? If someone knows please post. Is iron deficiency a multi billion dollar market. Yes. Fact. Is iron deficiency the worlds biggest deficiency ? Yes. Fact. And Shield have an effective oral well tolerated product. Fact. The company may not be moving as quick as people wish , if so move on. All the best. The small H2H error is the only real negative I can see in relation to the actual product ( and even that isn’t really representative of the product itself ) they actually seem quite bullish about how they can use the rest of the data. Otherwise , no great failing has been shown with the product itself. It’s BROAD LABEL FDA APPROVED for goodness sake ! Anyway GLA
peachie 74
21/5/2020
10:05
Sold out, back to 55p I think.
montyhedge
21/5/2020
09:59
And a couple of weeks ago everyone was happy when Tim Watts gave a couple of encouraging interviews about an imminent deal. PIs always over react both ways.....it is clear to me this is the time to buy if you are confident they will do a deal at some point in the next 3 or 4 months.
nobbygnome
21/5/2020
09:46
Key personnel jumping ship left right and centre. Poor revenue. Poor PR and and a feeling that they are not best placed to get the most from this product. And every interested US partner well aware that they have dwindling funds that won't last more than 10 months. All looking rosy
lako42
21/5/2020
09:08
Not a lot, if I were to hazard a wild, pessimistic guess :-)
daveboy1
Chat Pages: Latest  237  236  235  234  233  232  231  230  229  228  227  226  Older
ADVFN Advertorial
Your Recent History
LSE
STX
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200714 23:07:35